BR112013031652A2 - métodos de tratamento para doenças retinais - Google Patents

métodos de tratamento para doenças retinais

Info

Publication number
BR112013031652A2
BR112013031652A2 BR112013031652A BR112013031652A BR112013031652A2 BR 112013031652 A2 BR112013031652 A2 BR 112013031652A2 BR 112013031652 A BR112013031652 A BR 112013031652A BR 112013031652 A BR112013031652 A BR 112013031652A BR 112013031652 A2 BR112013031652 A2 BR 112013031652A2
Authority
BR
Brazil
Prior art keywords
neurotrophic factor
cdnf
manf
present
retinal disorder
Prior art date
Application number
BR112013031652A
Other languages
English (en)
Inventor
Wen Rong
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami filed Critical Univ Miami
Publication of BR112013031652A2 publication Critical patent/BR112013031652A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

abstract: the present invention provides methods of treating a retinal disorder comprising administering an effective amount of a neurotrophic factor to a subject having the retinal disorder. the neurotrophic factors useful in the invention include mesencephalic astrocyte-derived neurotrophic factor (manf) and conserved dopamine neurotrophic factor (cdnf). the present invention further comprises pharmaceutical compositions and kits containing manf and cdnf. tradução: resumo patente de invenção: "métodos de tratamento para doenças retinais". a presente invenção provê métodos de tratamento de um distúrbio retinal compreendendo administrar uma quantidade eficaz de fator neurotrófico a um indivíduo tendo o distúrbio retinal. os fatores neurotróficos úteis na invenção incluem fator neurotrófico derivado de astrócito mesenfálico (manf) e fator neurotrófico de dopamina conservada (cdnf). a presente invenção compreende ainda composições farmacêuticas e estojos contendo manf e cdnf.
BR112013031652A 2011-06-09 2012-06-08 métodos de tratamento para doenças retinais BR112013031652A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161495182P 2011-06-09 2011-06-09
PCT/US2012/041701 WO2012170918A2 (en) 2011-06-09 2012-06-08 Methods of treatment for retinal diseases

Publications (1)

Publication Number Publication Date
BR112013031652A2 true BR112013031652A2 (pt) 2019-09-24

Family

ID=47296781

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013031652A BR112013031652A2 (pt) 2011-06-09 2012-06-08 métodos de tratamento para doenças retinais

Country Status (12)

Country Link
US (2) US20140243264A1 (pt)
EP (1) EP2717903B1 (pt)
JP (1) JP6258197B2 (pt)
KR (1) KR20140063565A (pt)
CN (1) CN103987400B (pt)
AU (1) AU2012267519A1 (pt)
BR (1) BR112013031652A2 (pt)
CA (1) CA2838818A1 (pt)
EA (1) EA201400002A1 (pt)
ES (1) ES2594605T3 (pt)
WO (1) WO2012170918A2 (pt)
ZA (1) ZA201309557B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020182198A1 (en) 2001-03-20 2002-12-05 Commissiong John W. Dopaminergic neuronal survival-promoting factors and uses thereof
CN102083456B (zh) * 2008-03-25 2015-12-02 阿姆拉特斯治疗公司 神经退行性障碍
EP2717903B1 (en) 2011-06-09 2016-08-10 University Of Miami The neurotrophic factors manf and cdnf for use in the treatment of retinal disorders
EP3113788A4 (en) * 2014-03-05 2017-10-18 Lawrence M. Schwartz Methods and compositions for the protection of sensory cells
US20170252403A1 (en) * 2014-10-06 2017-09-07 Amarantus Bioscience Holdings, Inc. Methods and compositions for treating retinal disorders
CN107149673A (zh) * 2017-05-18 2017-09-12 山东大学 神经营养因子cdnf在制备缺血性脑血管疾病药物中的应用
SG11202009341TA (en) * 2018-03-29 2020-10-29 Helsingin Yliopisto C-terminal cdnf fragments, pharmaceutical compositions comprising same and uses thereof
CN110499330A (zh) * 2018-05-16 2019-11-26 上海市同济医院 重组腺相关病毒载体及其应用
CN108925783B (zh) * 2018-07-23 2021-09-21 浙江大学 烟粉虱manf基因或其表达的蛋白作为靶点在制备防治烟粉虱的药物中的应用
US20210299218A1 (en) * 2018-08-01 2021-09-30 Nanoneuron Therapeutics, Inc. Neuroprotective compositions and use thereof
DE102019123659A1 (de) 2019-09-04 2021-03-04 Sick Ag Verfahren zum Erstellen einer Karte, Verfahren zum Ermitteln einer Pose eines Fahrzeugs, Kartierungsvorrichtungen und Lokalisierungsvorrichtungen
EP3838912A1 (en) * 2019-12-20 2021-06-23 Herantis Pharma Oyj Retro-inverso peptides
CN111317814B (zh) * 2020-04-23 2020-12-18 中国中医科学院眼科医院 一种冰片联合神经营养因子组合物及应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4612012A (en) 1982-07-28 1986-09-16 White Thomas C Corneal implant
FR2744013B1 (fr) 1996-01-30 1998-04-24 Corneal Ind Dispositif de keratoprothese
IL138593A0 (en) * 1998-03-23 2001-10-31 Genentech Inc GFRα3 AND ITS USES
WO2001070158A1 (en) 1998-08-27 2001-09-27 Weyerhaeuser Company Absorbent composite having surface dryness
WO2001070174A2 (en) * 2000-03-21 2001-09-27 Curagen Corporation Vegf-modulated genes and methods employing them
EP1368468A4 (en) 2001-02-23 2005-02-16 Human Genome Sciences Inc 83 HUMAN SECRETED PROTEINS
US20020182198A1 (en) * 2001-03-20 2002-12-05 Commissiong John W. Dopaminergic neuronal survival-promoting factors and uses thereof
US20050177231A1 (en) 2001-09-10 2005-08-11 Ricci John L. Intra-ocular implant promoting direction guided cell growth
US7503155B2 (en) * 2002-08-26 2009-03-17 Meyers John G Method for packaging a tape substrate
US7452969B2 (en) * 2002-08-30 2008-11-18 Licentia Ltd Neurotrophic factor protein and uses thereof
US20060195915A1 (en) * 2002-08-30 2006-08-31 Licentia Ltd. Novel neurotrophic factor protein and uses thereof
CA2507036A1 (en) * 2002-12-02 2004-06-17 Genvec, Inc. Materials and methods for treating ocular-related disorders
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
US7223275B2 (en) 2003-05-27 2007-05-29 Yichieh Shiuey System for cutting the cornea of an eye
WO2005113017A2 (en) * 2004-04-22 2005-12-01 Florida Atlantic University Gfap-based gene therapy for treatment of retinal diseases
US9999497B2 (en) 2005-01-31 2018-06-19 Yichieh Shiuey Corneal implants and methods and systems for placement
US8868177B2 (en) * 2009-03-20 2014-10-21 ElectroCore, LLC Non-invasive treatment of neurodegenerative diseases
DE602005023550D1 (de) * 2005-12-14 2010-10-21 Licentia Ltd Verwendungen eines neurotrophischen Faktors
US20090196854A1 (en) * 2008-02-04 2009-08-06 Kytos Biosystems S.A. Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
CN102083456B (zh) * 2008-03-25 2015-12-02 阿姆拉特斯治疗公司 神经退行性障碍
FI20080326A0 (fi) * 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
US8109997B2 (en) 2009-01-18 2012-02-07 Eyeon Medical Ltd. Hydrophobic pseudo-endothelial implants for treating corneal edema
US9127083B2 (en) * 2009-10-30 2015-09-08 Ntf Therapeutics, Inc. Neurturin molecules
AU2010313456A1 (en) * 2009-10-30 2012-05-17 Ntf Therapeutics, Inc. Improved neurturin molecules
WO2012004291A1 (en) * 2010-07-06 2012-01-12 Nanologica Ab Improved method for stem cell differentiation in vivo by delivery of morphogenes with mesoporous silica and corresponding pharmaceutical active ingredients.
EP2717903B1 (en) 2011-06-09 2016-08-10 University Of Miami The neurotrophic factors manf and cdnf for use in the treatment of retinal disorders
US20140094413A1 (en) * 2012-04-02 2014-04-03 Washington State University Hepatocyte growth factor (hgf) mimics as therapeutic agents

Also Published As

Publication number Publication date
KR20140063565A (ko) 2014-05-27
CA2838818A1 (en) 2012-12-13
EP2717903B1 (en) 2016-08-10
EP2717903A2 (en) 2014-04-16
ZA201309557B (en) 2015-05-27
CN103987400B (zh) 2019-09-13
US10195251B2 (en) 2019-02-05
EP2717903A4 (en) 2015-04-29
JP2014518204A (ja) 2014-07-28
US20180028607A1 (en) 2018-02-01
US20140243264A1 (en) 2014-08-28
AU2012267519A1 (en) 2014-01-09
WO2012170918A2 (en) 2012-12-13
NZ618743A (en) 2016-02-26
JP6258197B2 (ja) 2018-01-17
ES2594605T3 (es) 2016-12-21
WO2012170918A3 (en) 2014-05-08
CN103987400A (zh) 2014-08-13
EA201400002A1 (ru) 2014-08-29

Similar Documents

Publication Publication Date Title
BR112013031652A2 (pt) métodos de tratamento para doenças retinais
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112015010477A2 (pt) combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas
BR112014008036A2 (pt) tratamento de rinite
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
CR20130580A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2
BR112014008731A2 (pt) tratamento de esclerose múltipla com combinação de laquinimode e fingolimode
BR112014003704A2 (pt) moduladores ror gama
BR112013027554A2 (pt) "usos de compostos no tratamento de mal de alzheimer, doença de huntington, autismo e outros distúrbios"
MX2013004329A (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
BR112013029256A2 (pt) "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
BR112015008297A2 (pt) antagonistas de mglu2/3 para o tratamento de distúrbios autistas
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
BR112013001299A2 (pt) composições farmacêuticas e respectivo uso e métodos de tratamento de diabetes e doenças correlatas em paciente humano
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
BR112013001301A2 (pt) processo para preparar uma composição líquida farmacêutica compreendendo imunoglobulina g humana e composição líquida farmacêutica contendo imunoglobulina g humana
BR112013004562A2 (pt) 2-óxi-quinolina-3-carboxamidas substituídas como moduladores kcnq2/3
BR112013029182A2 (pt) método para o tratamento de malignidades sólidas incluindo malignidades sólidas avançadas ou metastáticas
BR112013018598A2 (pt) composição farmacêutica, método para tratar uma doença cardíaca, uso de (s)-metil-3-[4-(2-hidroxi-3-[4-(2-hidroxi-3-isopropilamino) propoxi] fenilpropionato, e, método para controlar frequência cardíaca
BR112014004447A2 (pt) bifenilcarboxamidas como inibidores de quinase rock
UY33568A (es) Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes.

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.